Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Accounts Payables: 2019-2025

Historic Accounts Payables for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to $14.3 million.

  • Eton Pharmaceuticals' Accounts Payables rose 431.26% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.3 million, marking a year-over-year increase of 431.26%. This contributed to the annual value of $4.2 million for FY2024, which is 125.49% up from last year.
  • Per Eton Pharmaceuticals' latest filing, its Accounts Payables stood at $14.3 million for Q3 2025, which was up 17.44% from $12.1 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Accounts Payables ranged from a high of $14.3 million in Q3 2025 and a low of $1.1 million during Q3 2022.
  • Moreover, its 3-year median value for Accounts Payables was $2.3 million (2023), whereas its average is $4.5 million.
  • As far as peak fluctuations go, Eton Pharmaceuticals' Accounts Payables tumbled by 67.80% in 2022, and later skyrocketed by 469.25% in 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Accounts Payables (Quarterly) stood at $1.8 million in 2021, then decreased by 0.45% to $1.8 million in 2022, then climbed by 4.64% to $1.8 million in 2023, then spiked by 125.49% to $4.2 million in 2024, then skyrocketed by 431.26% to $14.3 million in 2025.
  • Its last three reported values are $14.3 million in Q3 2025, $12.1 million for Q2 2025, and $4.9 million during Q1 2025.